Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.

Huang J, Kang BH, Ishida E, Zhou T, Griesman T, Sheng Z, Wu F, Doria-Rose NA, Zhang B, McKee K, O’Dell S, Chuang GY, Druz A, Georgiev IS, Schramm CA, Zheng A, Joyce MG, Asokan M, Ransier A, Darko S, Migueles SA, Bailer RT, Louder MK, Alam SM, Parks R, Kelsoe G, Von Holle T, Haynes BF, Douek DC, Hirsch V, Seaman MS, Shapiro L, Mascola JR, Kwong PD, Connors M. Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. Immunity. 2016 Nov 15;45(5):1108-1121.

Increased frequencies of CD8+CD57+ T cells are associated with antibody neutralization breadth against HIV in viraemic controllers.

Palmer CD, Romero-Tejeda M, Scully EP, Lockhart A, Seaman MS, Goldenthal A, Piechocka- Trocha A, Walker B, Chibnik LB, Jost S, Porichis F. Increased frequencies of CD8+CD57+ T cells are associated with antibody neutralization breadth against HIV in viraemic controllers. (2016) Journal of the International AIDS Society. 19(1):21136

A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo.

Freund NT, Horwitz JA, Nogueira L, Sievers SA, Scharf L, Scheid JF, Gazumyan A, Liu C, Velinzon K, Goldenthal A, Sanders RW, Moore JP, Bjorkman PJ, Seaman MS, Walker BD, Klein F, Nussenzweig MC. A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo. PLoS Pathogens. 2015, 11(10):e1005238.

Lambda light chain bias associated with enhanced binding and function of anti-HIV Env glycoprotein antibodies.

Sajadi MM, Farshidpour M, Brown EP, Ouyang X, Seaman MS, Pazgier M, Ackerman ME, Robinson H, Tomaras G, Parsons MS, Charurat M, DeVico AL, Redfield RR, Lewis GK. Lambda light chain bias associated with enhanced binding and function of anti-HIV Env glycoprotein antibodies. J. Infect. Dis. 2016, 213(1):e1005431.

Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site.

Gristick HB, von Boehmer L, West AP Jr, Schamber M, Gazumyan A, Golijanin J, Seaman MS, Fätkenheuer G, Klein F, Nussenzweig MC, Bjorkman PJ. Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Nat Struct Mol Biol. 2016, 23(10):906-915.

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.

Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, Garrity J, Rist M, Rademeyer C, Yoon H, Lapedes A, Gao H, Greene K, Louder MK, Kong R, Karim SA, Burton DR, Barouch DH, Nussenzweig MC, Mascola JR, Morris L, Montefiori DC, Korber B, Seaman MS. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathog. 2016, 2(3):e1005520.

Anti-HIV-1 Antibody 3BNC117 Suppresses Rebound in Humans During Treatment Interruption.

Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lorenzi JCC, Feldmann A, Nogueira L, Oliveira T, Shimeliovich I, Patel R, Burke L, Cohen Y, Hadrigan S, Settler A, Witmer-Pack M, West, Jr AP, Juelg B, Keler T, Hawthorne T, Zingman B, Gulick RM, Pfeifer N, Learn GH, Seaman MS, Klein F, Schlesinger SJ, Walker B, Hahn BH, Nussenzweig MC, Caskey M. Anti-HIV-1 Antibody 3BNC117 Suppresses Rebound in Humans During Treatment Interruption. Nature. 2016, 535(7613): 556-60.

Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA.

Lorenzi JC, Cohen YZ, Cohn LB, Kreider EF, Barton JP, Learn GH, Oliveira T, Lavine CL, Horwitz JA, Settler A, Jankovic M, Seaman MS, Chakraborty AK, Hahn BH, Caskey M, Nussenzweig MC. Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA. Proc Natl Acad Sci U S A. 2016 Dec 6;113(49):E7908-E7916.

Antibody responses after analytic treatment interruption in human immunodeficiency virus-1-infected individuals on early initiated antiretroviral therapy.

Stephenson KE, Neubauer GH, Bricault CA, Shields J, Bayne M, Reimer U, Pawlowski N, Knaute T, Zerweck J, Seaman MS, Rosenberg ES, Barouch DH. Antibody responses after analytic treatment interruption in human immunodeficiency virus-1-infected individuals on early initiated antiretroviral therapy. Open Forum Infect Dis. 2016; 3:ofw100.

Production of mucosally transmissible SHIV challenge stocks from HIV-1 circulating recombinant form 01_AE env sequences.

Tartaglia LJ, Chang HW, Lee BC, Abbink P, Ng’ang’a D, Boyd M, Lavine CL, Lim SY, Sanisetty S, Whitney JB, Seaman MS, Rolland M, Tovanabutra S, Ananworanich J, Robb ML, Kim JH, Michael NL, Barouch DH. Production of mucosally transmissible SHIV challenge stocks from HIV-1 circulating recombinant form 01_AE env sequences. PLoS Pathog. 2016; 12:e1005431.